Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $38.00 Price Target at JPMorgan Chase & Co.

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price objective upped by JPMorgan Chase & Co. from $33.00 to $38.00 in a research report sent to investors on Thursday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Other analysts have also recently issued research reports about the stock. HC Wainwright upped their price objective on shares of Syndax Pharmaceuticals from $49.00 to $51.00 and gave the company a “buy” rating in a research note on Monday. UBS Group assumed coverage on Syndax Pharmaceuticals in a research report on Thursday, October 24th. They issued a “buy” rating and a $37.00 price target for the company. StockNews.com raised Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, November 15th. The Goldman Sachs Group raised their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, Barclays upped their price objective on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a report on Thursday, August 15th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $37.64.

Syndax Pharmaceuticals Price Performance

Shares of SNDX stock opened at $15.60 on Thursday. Syndax Pharmaceuticals has a 1-year low of $15.00 and a 1-year high of $25.34. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -4.30 and a beta of 0.92. The stock has a 50 day simple moving average of $18.66 and a 200-day simple moving average of $20.05.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.15. The company had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $9.16 million. During the same period in the prior year, the firm earned ($0.73) EPS. Analysts anticipate that Syndax Pharmaceuticals will post -3.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Syndax Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in Syndax Pharmaceuticals by 3.5% during the third quarter. Geode Capital Management LLC now owns 1,977,082 shares of the company’s stock worth $38,066,000 after purchasing an additional 66,459 shares during the period. Barclays PLC grew its holdings in shares of Syndax Pharmaceuticals by 143.4% in the third quarter. Barclays PLC now owns 187,629 shares of the company’s stock valued at $3,612,000 after purchasing an additional 110,535 shares in the last quarter. Y Intercept Hong Kong Ltd increased its stake in Syndax Pharmaceuticals by 319.4% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 81,302 shares of the company’s stock worth $1,565,000 after buying an additional 61,916 shares during the period. Two Sigma Advisers LP lifted its holdings in Syndax Pharmaceuticals by 7.7% during the 3rd quarter. Two Sigma Advisers LP now owns 669,352 shares of the company’s stock worth $12,885,000 after buying an additional 48,100 shares in the last quarter. Finally, Sphera Funds Management LTD. lifted its holdings in Syndax Pharmaceuticals by 25.9% during the 3rd quarter. Sphera Funds Management LTD. now owns 1,034,846 shares of the company’s stock worth $19,921,000 after buying an additional 212,799 shares in the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).